BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014; 4(3): 163-188 [PMID: 25332915 DOI: 10.5662/wjm.v4.i3.163] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Cismondi IA, Kohan R, Adams H, Bond M, Brown R, Cooper JD, de Hidalgo PK, Holthaus SM, Mole SE, Mugnaini J, de Ramirez AM, Pesaola F, Rautenberg G, Platt FM, Noher de Halac I. Guidelines for incorporating scientific knowledge and practice on rare diseases into higher education: neuronal ceroid lipofuscinoses as a model disorder. Biochim Biophys Acta 2015;1852:2316-23. [PMID: 26117801 DOI: 10.1016/j.bbadis.2015.06.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
2 Kontoghiorghes GJ, Kolnagou A, Demetriou T, Neocleous M, Kontoghiorghe CN. New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications. Int J Mol Sci 2021;22:5546. [PMID: 34074010 DOI: 10.3390/ijms22115546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kontoghiorghes GJ, Kontoghiorghe CN. Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells 2020;9:E1456. [PMID: 32545424 DOI: 10.3390/cells9061456] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
4 Ito MK, Watts GF. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. Drugs 2015;75:1715-24. [PMID: 26370207 DOI: 10.1007/s40265-015-0466-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
5 Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ. Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology. Molecules 2015;20:20841-72. [PMID: 26610453 DOI: 10.3390/molecules201119725] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
6 Kontoghiorghes GJ, Kontoghiorghe CN. Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology. Expert Opinion on Investigational Drugs 2019;28:593-603. [DOI: 10.1080/13543784.2019.1631284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
7 Horiuchi Y, Ohkawa R, Lai SJ, Shimano S, Hagihara M, Tohda S, Kameda T, Tozuka M. Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads. Biosci Rep 2019;39:BSR20190213. [PMID: 30867253 DOI: 10.1042/BSR20190213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Horiuchi Y, Ohkawa R, Lai SJ, Yamazaki A, Ikoma H, Yano K, Kameda T, Tozuka M. Characterization of the cholesterol efflux of apolipoprotein E-containing high-density lipoprotein in THP-1 cells. Biol Chem 2019;400:209-18. [PMID: 30210053 DOI: 10.1515/hsz-2018-0284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kontoghiorghes GJ. Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. Int J Mol Sci 2022;23:6735. [PMID: 35743183 DOI: 10.3390/ijms23126735] [Reference Citation Analysis]
10 Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol 2016; 6(1): 1-19 [PMID: 27019793 DOI: 10.5662/wjm.v6.i1.1] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
11 Kontoghiorghes GJ. Ethics in Medicines: Exposing Unethical Practices and Corruption in All Sectors of Medicines Is Essential for Improving Global Public Health and Saving Patients' Lives. Medicines (Basel) 2021;8:54. [PMID: 34564096 DOI: 10.3390/medicines8090054] [Reference Citation Analysis]
12 Qian J, Sullivan BP, Peterson SJ, Berkland C. Nonabsorbable Iron Binding Polymers Prevent Dietary Iron Absorption for the Treatment of Iron Overload. ACS Macro Lett 2017;6:350-3. [PMID: 35610854 DOI: 10.1021/acsmacrolett.6b00945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
13 Makarova EV, Krysanov IS, Valilyeva TP, Vasiliev MD, Zinchenko RA. Evaluation of orphan diseases global burden. Eur J Transl Myol 2021;31. [PMID: 33985324 DOI: 10.4081/ejtm.2021.9610] [Reference Citation Analysis]
14 Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:4073-8. [PMID: 28008230 DOI: 10.2147/DDDT.S117080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Esteban-bueno G, Díaz-anadón LR, Rodríguez González A, Navarro Cabrero M, Berenguel Hernández AM. Protocolo genético en Atención Primaria para enfermedades raras: el síndrome de Wolfram como prototipo. Atención Primaria 2022;54:102285. [DOI: 10.1016/j.aprim.2022.102285] [Reference Citation Analysis]
16 Kontoghiorghes GJ. Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines (Basel) 2021;8:36. [PMID: 34357152 DOI: 10.3390/medicines8070036] [Reference Citation Analysis]
17 Kontoghiorghes GJ, Kolnagou A, Kontoghiorghe CN, Mourouzidis L, Timoshnikov VA, Polyakov NE. Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications. Medicines (Basel) 2020;7:E45. [PMID: 32751493 DOI: 10.3390/medicines7080045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
18 Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:465-81. [PMID: 26893541 DOI: 10.2147/DDDT.S79458] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
19 Timson DJ. Value of predictive bioinformatics in inherited metabolic diseases. World J Med Genet 2015; 5(3): 46-51 [DOI: 10.5496/wjmg.v5.i3.46] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
20 Kontoghiorghes GJ, Kolnagou A, Fetta S, Kontoghiorghe CN. Conventional and Unconventional Approaches for Innovative Drug Treatments in COVID-19: Looking Outside of Plato's Cave. Int J Mol Sci 2021;22:7208. [PMID: 34281262 DOI: 10.3390/ijms22137208] [Reference Citation Analysis]
21 Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia. Mediterr J Hematol Infect Dis 2020;12:e2020011. [PMID: 31934321 DOI: 10.4084/MJHID.2020.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]